Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Abstract

A monoclonal antibody called mirikizumab is used to treat ulcerative colitis. It is marketed under the Omvoh brand. It is intended to bind to interleukin-23 (IL-23) and obstruct its function. Upper respiratory tract (nose and throat) infections, headaches, rashes, and injection site responses (when administered by subcutaneous injection) are the most frequent adverse effects. In the United States in October 2023 and the European Union in May 2023, mirikizumab was authorized for medicinal use. For the treatment of people with moderately to highly active ulcerative colitis who have not responded well to, have lost responsiveness to, or are intolerant to either biologic therapy or conventional therapy, mirikizumab is suggested. A subset of people with ulcerative colitis (UC) do not react to currently available medications, despite advancements in UC medical therapy. Many innovative medications have recently acquired regulatory approval for use in UC, or are in the latter stages of development. The novel antibody mirikizumab, which is given intravenously (IV), binds to the inflammatory protein interleukin 23 and inhibits its function, preventing inflammation from being triggered. For individuals with moderately to highly active UC, mirikizumab would therefore provide an additional therapy choice if legalized.